BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23934752)

  • 21. Platelet-type von Willebrand disease: Local disorder of the platelet GPIbα β-switch drives high-affinity binding to von Willebrand factor.
    Tischer A; Machha VR; Moon-Tasson L; Auton M
    J Thromb Haemost; 2019 Dec; 17(12):2022-2034. PubMed ID: 31448872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A p.Arg127Gln variant in GPIbα LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD.
    Bury L; Falcinelli E; Kuchi Bhotla H; Mezzasoma AM; Guglielmini G; Tischer A; Moon-Tasson L; Auton M; Gresele P
    Blood Adv; 2022 Apr; 6(7):2236-2246. PubMed ID: 34619770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes.
    Othman M
    Semin Thromb Hemost; 2007 Nov; 33(8):780-6. PubMed ID: 18175283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies.
    Frontroth JP; Favaloro EJ
    Methods Mol Biol; 2017; 1646():473-494. PubMed ID: 28804849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
    Kanaji S; Morodomi Y; Weiler H; Zarpellon A; Montgomery RR; Ruggeri ZM; Kanaji T
    Haematologica; 2022 Sep; 107(9):2133-2143. PubMed ID: 35142156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF.
    Yago T; Lou J; Wu T; Yang J; Miner JJ; Coburn L; López JA; Cruz MA; Dong JF; McIntire LV; McEver RP; Zhu C
    J Clin Invest; 2008 Sep; 118(9):3195-207. PubMed ID: 18725999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
    Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
    Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations.
    Dumas JJ; Kumar R; McDonagh T; Sullivan F; Stahl ML; Somers WS; Mosyak L
    J Biol Chem; 2004 May; 279(22):23327-34. PubMed ID: 15039442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Randi AM; Shindler KS; Tuley EA; Rustagi PK; Sadler JE
    J Biol Chem; 1993 Sep; 268(27):20497-501. PubMed ID: 8376405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of p.W246L as a novel mutation in the GP1BA gene responsible for platelet-type von Willebrand disease.
    Woods AI; Sanchez-Luceros A; Bermejo E; Paiva J; Alberto MF; Grosso SH; Kempfer AC; Lazzari MA
    Semin Thromb Hemost; 2014 Mar; 40(2):151-60. PubMed ID: 24474090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease.
    Kaur H; Corscadden K; Ware J; Othman M
    Thromb Haemost; 2017 Feb; 117(3):543-555. PubMed ID: 28004055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetics of type 2B von Willebrand disease: "true 2B," "tricky 2B," or "not 2B." What are the modifiers of the phenotype?
    Othman M; Favaloro EJ
    Semin Thromb Hemost; 2008 Sep; 34(6):520-31. PubMed ID: 19085651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
    Weiss HJ; Sussman II
    Blood; 1986 Jul; 68(1):149-56. PubMed ID: 3487353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor.
    Hilbert L; Jenkins PV; Gaucher C; Meriane E; Collins PW; Pasi KJ; Mazurier C
    Thromb Haemost; 2000 Aug; 84(2):188-94. PubMed ID: 10959688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.
    Larsen DM; Haberichter SL; Gill JC; Shapiro AD; Flood VH
    Haemophilia; 2013 Jul; 19(4):590-4. PubMed ID: 23496210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.